- Home
- LDTC vs BCLI Comparison
LDTC vs BCLI Comparison
Compare LDTC & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- BCLI
- Stock Information
- Founded
- LDTC 2007
- BCLI 2000
- Country
- LDTC Canada
- BCLI United States
- Employees
- LDTC N/A
- BCLI N/A
- Industry
- LDTC Blank Checks
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDTC Finance
- BCLI Health Care
- Exchange
- LDTC Nasdaq
- BCLI Nasdaq
- Market Cap
- LDTC 7.9M
- BCLI 25.0M
- IPO Year
- LDTC N/A
- BCLI N/A
- Fundamental
- Price
- LDTC $0.28
- BCLI $2.12
- Analyst Decision
- LDTC Buy
- BCLI Strong Buy
- Analyst Count
- LDTC 3
- BCLI 1
- Target Price
- LDTC $1.00
- BCLI $30.00
- AVG Volume (30 Days)
- LDTC 228.2K
- BCLI 86.5K
- Earning Date
- LDTC 08-14-2024
- BCLI 11-12-2024
- Dividend Yield
- LDTC N/A
- BCLI N/A
- EPS Growth
- LDTC N/A
- BCLI N/A
- EPS
- LDTC N/A
- BCLI N/A
- Revenue
- LDTC $6,052,694.00
- BCLI N/A
- Revenue This Year
- LDTC N/A
- BCLI N/A
- Revenue Next Year
- LDTC $2.28
- BCLI N/A
- P/E Ratio
- LDTC N/A
- BCLI N/A
- Revenue Growth
- LDTC 2.76
- BCLI N/A
- 52 Week Low
- LDTC $0.24
- BCLI $1.95
- 52 Week High
- LDTC $11.20
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- LDTC 41.42
- BCLI 31.68
- Support Level
- LDTC $0.24
- BCLI $1.97
- Resistance Level
- LDTC $0.29
- BCLI $2.68
- Average True Range (ATR)
- LDTC 0.03
- BCLI 0.29
- MACD
- LDTC 0.01
- BCLI 0.05
- Stochastic Oscillator
- LDTC 77.92
- BCLI 21.62
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.